Table 3.
LC‐ESI‐MS analysis of N‐glycans released from antibody 2G12 transiently expressed in wild‐type N. benthamiana and the F‐KO #6‐10‐6, X‐KO #34‐4‐4 and FX‐KO #20‐4 lines
| Glycan acronym | Wild type | F‐KO #6‐10‐6 | X‐KO #34‐4‐4 | FX‐KO #20‐4 |
|---|---|---|---|---|
| % of total | ||||
| Not glyc | 14.5 | 14.0 | 14.0 | 15.8 |
| Man7 | 2.0 | 1.3 | 1.8 | 2.6 |
| Man8 | 5.3 | 1.3 | 2.3 | 7.8 |
| Man9 | 1.5 | 3.7 | ||
| GnM | 0.5 | 1.9 | 2.8 | |
| GnGn | 1.9 | 4.7 | 20.8 | 65.4 |
| MMXF | 1.6 | |||
| GnMXF | 3.4 | |||
| GnGnXF | 62.4 | |||
| MMX | 0.9 | |||
| GnUX | 1.4 | |||
| GnMX | 0.5 | 7.2 | ||
| GnGnX | 5.0 | 67.6 | ||
| MMF | 3.0 | |||
| GnMF | 0.3 | 4.9 | ||
| GnGnF | 1.8 | 50.3 | ||
Symbols: X = β‐1,2‐xylosylated glycopeptides, F = α‐1,3‐fucosylated glycopeptides. The dominant glycan structure in all samples is GnGn/X/F/XF (bold). Glycan acronyms are based on proglycan nomenclature (http://www.proglycan.com/sites/default/public/pdf/nomen_2007.pdf).